GGrantIndex
← Search

Microarray

$241,660P30FY2009CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

Parallel analysis of multiple genes on the DNA or RNA level is becoming more and more important, because cancer is identified as a disease that involves multiple genes. To study this cascade of genetic alterations, analysis on a single-gene level cannot be the final answer. Microarray analysis is state-of-the-art technology for fulfilling these scientific needs. The OSUCCC Microarray Shared Resource (MASR) was established as a "developing" Shared Resource in 1998 initially serving investigators in the Molecular Biology and Cancer Genetics Program with genome wide expression analysis, and subsequently becoming one of the Shared Resources for the entire OSUCCC offering genome wide expression analysis using Affymetrix GeneChips. In September 2002, quantification of RNA integrity by capillary electrophoresis became available, and since September 2003, the MASR has offered validation of microarray results, via an array-based design of primers for real-time PCR. For projects utilizing any of these technologies, the MASR offers multiple services, including experimental design consultation, sample processing, hybridization, scanning, full statistical analysis and consultation, and validation of results. Newer services, such as custom arrays and SNPs are soon to be available. The MASR trains investigators to upload their results to Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) since this becomes mandatory for publication in many journals. The MASR website (www.dnaarrays.org) contains information about services, publications and downloadable protocols and order forms. The MASR offers timely, technical and professional expertise that promotes high quality science at a competitive price. To support OSUCCC researchers, several hundred RNA samples are processed each year for genome wide expression analysis. In addition, several hundred RNA samples are processed for integrity quantification. During 2003, the MASR worked with 30 investigators, 95% of who are CCC members affiliated with four CCC programs, and the amount of MASR service to these members increased 72% over the previous year. There are 42 current or pending grants from OSUCCC members that include utilization of the MASR. The OSUCCC has provided $2.1 M in Institutional support to establish and run the MASR as a "developing" Shared Resource. We now request CCSG funding that will provide `30% of the total support for this important full Shared Resource over the next five years.

View original record on NIH RePORTER →
Microarray · GrantIndex